Adelmidrol: A New Promising Antioxidant and Anti-Inflammatory Therapeutic Tool in Pulmonary Fibrosis

Roberta Fusco, Marika Cordaro, Tiziana Genovese, Daniela Impellizzeri, Rosalba Siracusa, Enrico Gugliandolo, Alessio Filippo Peritore, Ramona D'Amico, Rosalia Crupi, Salvatore Cuzzocrea, Rosanna Di Paola. Antioxidants (Basel). 2020;9(7):601.

Laboratory studyOther animalsWith adelmidrol (a PEA analogue, tested alone)

This study tested palmitoylethanolamide together with adelmidrol (a PEA analogue, tested alone). Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.

Design: Laboratory study
Subjects: Mice given intratracheal bleomycin to induce lung fibrosis (numbers not stated in the abstract)
Dose used in the study: Adelmidrol 10 mg/kg daily; route not stated in the abstract
Duration: 21 days
What was measured: Survival, body weight, airway inflammatory cell infiltration, myeloperoxidase, cytokines (IL-6, IL-1-beta, TNF-alpha, TGF-beta), oxidative markers (MDA, SOD, GSH, nitric oxide), JAK2/STAT3 and NF-kappa-B pathways, lung histology, mast cell degranulation, chymase and collagen.

What the authors reported

This laboratory study found that adelmidrol-treated mice showed:

Less airway inflammatory infiltration, lower myeloperoxidase and cytokine expression, restored antioxidant levels with less oxidant burden and nitric oxide.
Modulation of JAK2/STAT3 and NF-kappa-B.
On histology, less injury, mast cell degranulation, chymase activity and collagen deposition.
No numbers are given in the abstract.

Limits of this study

A mouse model of lung fibrosis; it cannot show effect in people or animals treated in practice. Salvatore Cuzzocrea is a co-inventor with Epitech Group on a patent covering adelmidrol, the molecule studied, and on other Epitech patents.

Source

PubMed 32660140 · doi:10.3390/antiox9070601

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.